Pancreatic Cancer Research

ResearcherBeckman Research InstituteActive in the last 2 years

Satoshi Nishiwada

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-1462-7459; OpenAlex author ID A5038253697. Sources: OpenAlex.

Their work

Papers
29 (first author 4, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
68
Papers, trials and grants by year

2015: 8 papers · 2016: 4 papers · 2017: none · 2018: 1 paper · 2019: 3 papers · 2020: 1 paper · 2021: 3 papers · 2022: 3 papers · 2023: 4 papers · 2024: 1 paper · 2025: 1 paper

Papers 29

  1. An axon guidance-related microRNA panel identifies perivascular plexus local recurrence following curative surgery in patients with pancreatic cancer. Co-author DOI 10.1007/s00535-025-02260-w↗
  2. Clinical impact of carbonic anhydrase 9 expression on neoadjuvant chemoradiotherapy in pancreatic ductal adenocarcinoma. First author DOI 10.1016/j.pan.2024.08.003↗
  3. Importance of triple tumor markers as biomarkers in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ags3.12629↗
  4. Clinical significance and functional role of adhesion G-protein-coupled receptors in human pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41416-022-02057-1↗
  5. Identification of Nectin Family Interactive Gene Panel and Stratification of Clinical Outcomes in Patients with Pancreatic Cancer. First author DOI 10.1097/xcs.0000000000000808↗
  6. Pancreatic ductal adenocarcinoma arising from the pancreatic parenchyma compressed by a huge pancreatic lipoma: a case report. Co-author DOI 10.1186/s40792-023-01720-w↗
  7. Integrative analysis identifies activated anti-tumor immune microenvironment in lung metastasis of pancreatic cancer. First author DOI 10.1007/s10147-022-02131-x↗
  8. An Exosome-based Transcriptomic Signature for Noninvasive, Early Detection of Patients With Pancreatic Ductal Adenocarcinoma: A Multicenter Cohort Study. Co-author DOI 10.1053/j.gastro.2022.06.090↗
  9. Transcriptomic Profiling Identifies an Exosomal microRNA Signature for Predicting Recurrence Following Surgery in Patients With Pancreatic Ductal Adenocarcinom… Co-author DOI 10.1097/sla.0000000000004993↗
  10. A gene expression signature for predicting response to neoadjuvant chemoradiotherapy in pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ijc.33284↗
  11. Identification of laminin γ2 as a prognostic and predictive biomarker for determining response to gemcitabine-based therapy in pancreatic ductal adenocarcinoma. First author DOI 10.1016/j.ejca.2020.12.031↗
  12. Clinical relevance of CD70 expression in resected pancreatic cancer: Prognostic value and therapeutic potential. Co-author DOI 10.1016/j.pan.2021.01.013↗
  13. A MicroRNA Signature Identifies Pancreatic Ductal Adenocarcinoma Patients at Risk for Lymph Node Metastases. Co-author DOI 10.1053/j.gastro.2020.04.057↗
  14. Risk Factors for Late-Onset Gastrointestinal Hemorrhage After Pancreatoduodenectomy for Pancreatic Cancer. Co-author DOI 10.1007/s00268-018-4791-7↗
  15. A Comparison Between Plastic and Metallic Biliary Stent Placement in Patients Receiving Preoperative Neoadjuvant Chemoradiotherapy for Resectable Pancreatic Ca… Co-author DOI 10.1007/s00268-018-4820-6↗
  16. Phase II Study of the Triple Combination Chemotherapy of SOXIRI (S-1/Oxaliplatin/Irinotecan) in Patients with Unresectable Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1634/theoncologist.2018-0900↗
  17. Prognostic factors for actual long-term survival in the era of multidisciplinary treatment for pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00423-018-1709-7↗
  18. Do pancrelipase delayed-release capsules have a protective role against nonalcoholic fatty liver disease after pancreatoduodenectomy in patients with pancreati… Co-author DOI 10.1002/jhbp.318↗
  19. Prognosis after surgical treatment for pancreatic cancer in patients aged 80 years or older: a multicenter study. Co-author DOI 10.1002/jhbp.320↗
  20. Phase I study assessing the feasibility of the triple combination chemotherapy of SOXIRI (S-1/oxaliplatin/irinotecan) in patients with unresectable pancreatic … Co-author DOI 10.1007/s00280-015-2928-z↗
  21. Factors associated with failure to complete adjuvant chemotherapy in pancreatic cancer. Co-author DOI 10.1016/j.amjsurg.2015.10.034↗
  22. Prognostic Significance of Muscle Attenuation in Pancreatic Cancer Patients Treated with Neoadjuvant Chemoradiotherapy. Co-author DOI 10.1007/s00268-015-3205-3↗
  23. Optimal indication of neoadjuvant chemoradiotherapy for pancreatic cancer. Co-author DOI 10.1007/s00423-015-1304-0↗
  24. Postoperative prognosis of pancreatic cancer with para-aortic lymph node metastasis: a multicenter study on 822 patients. Co-author DOI 10.1007/s00535-014-1005-4↗
  25. Potential role of surgical resection for pancreatic cancer in the very elderly. Co-author DOI 10.1016/j.pan.2015.03.015↗
  26. Impact of Smoking on Pancreatic Cancer Patients Receiving Current Chemotherapy. Co-author DOI 10.1097/mpa.0000000000000395↗
  27. Nectin-4 expression contributes to tumor proliferation, angiogenesis and patient prognosis in human pancreatic cancer. Co-author DOI 10.1186/s13046-015-0144-7↗
  28. Impact of Preoperative Biliary Drainage on Long-Term Survival in Resected Pancreatic Ductal Adenocarcinoma: A Multicenter Observational Study. Co-author DOI 10.1245/s10434-015-4618-9↗
  29. Clinical significance of CD155 expression in human pancreatic cancer. Co-author PMID 25862891↗

Closest collaborators

The 25 strongest of 68 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Masayuki Sho · 28 shared papers, 2015–2025 · strength 2.80
  2. Minako Nagai · 24 shared papers, 2015–2025 · strength 2.37
  3. Kota Nakamura · 14 shared papers, 2018–2025 · strength 1.86
  4. Taichi Terai · 8 shared papers, 2021–2025 · strength 1.39
  5. Takahiro Akahori · 19 shared papers, 2015–2022 · strength 1.35
  6. Satoshi Yasuda · 9 shared papers, 2015–2025 · strength 1.24
  7. Yuichiro Kohara · 5 shared papers, 2023–2025 · strength 0.95
  8. Kenji Nakagawa · 8 shared papers, 2018–2023 · strength 0.90
  9. Ajay Goel · 6 shared papers, 2020–2023 · strength 0.78
  10. Naoya Ikeda · 9 shared papers, 2015–2021 · strength 0.72
  11. Toshihiro Tanaka · 6 shared papers, 2015–2025 · strength 0.58
  12. Kensuke Yamamura · 4 shared papers, 2020–2023 · strength 0.55
  13. Yoshiyuki Nakajima · 11 shared papers, 2015–2016 · strength 0.52
  14. Shoichi Kinoshita · 11 shared papers, 2015–2016 · strength 0.52
  15. Kimihiko Kichikawa · 7 shared papers, 2015–2019 · strength 0.45
  16. Tadataka Takagi · 3 shared papers, 2021–2023 · strength 0.43
  17. Suguru Yamada · 3 shared papers, 2022–2023 · strength 0.40
  18. Yasuhiro Kodera · 3 shared papers, 2022–2023 · strength 0.40
  19. Hiroaki Yanagimoto · 7 shared papers, 2015–2019 · strength 0.36
  20. Sohei Satoi · 7 shared papers, 2015–2019 · strength 0.36
  21. Tsutomu Fujii · 2 shared papers, 2022–2023 · strength 0.29
  22. Hideyuki Nishiofuku · 4 shared papers, 2015–2019 · strength 0.24
  23. In Woong Han · 2 shared papers, 2022 · strength 0.23
  24. Eunsung Jun · 2 shared papers, 2022 · strength 0.23
  25. Joon Oh Park · 2 shared papers, 2022 · strength 0.23

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.